Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Melanoma 22Uveal Melanoma 3Carcinoma, Basal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Melanoma, Cutaneous Malignant 1Lymphoma 1Lung Neoplasms 1Locally Advanced Melanoma 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 22Ipilimumab 17Nivolumab 16pembrolizumab 11Temozolomide 9encorafenib 8dabrafenib 8binimetinib 8Magnetic Resonance Spectroscopy 6trametinib 5Bevacizumab 5CTLA-4 Antigen 4cobimetinib 3Thalidomide 3Radiotherapy 3Paclitaxel 3entrectinib 2cediranib 2Vemurafenib 2Spermine Synthase 2Specimen Handling 2Radiation 2Pemetrexed 2Opdualag 2Drug Therapy 2Carboplatin 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 214-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2130-nm albumin-bound paclitaxel 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × relatlimab × Dermatologic × Clear all
NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡